Aptose Biosciences (TSX:APS) Change In Payables And Accrued Expense : C$-8.39 Mil (TTM As of Mar. 2025)

View and export this data going back to 1993. Start your Free Trial

What is Aptose Biosciences Change In Payables And Accrued Expense?

Aptose Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was C$2.42 Mil. It means Aptose Biosciences's Accounts Payable & Accrued Expense increased by C$2.42 Mil from Dec. 2024 to Mar. 2025 .

Aptose Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was C$-15.45 Mil. It means Aptose Biosciences's Accounts Payable & Accrued Expense declined by C$15.45 Mil from Dec. 2023 to Dec. 2024 .

Aptose Biosciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Aptose Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Change In Payables And Accrued Expense Chart

Aptose Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

1.61

1.85

5.80

3.88

-15.45

Aptose Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-4.24	0.78	-4.02	-7.57	2.42

Aptose Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-8.39 Mil.

Aptose Biosciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptose Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (TSX:APS) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

APTOF:USA 0UI8:UK LTI0:Germany

Address

66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, CAN, M5K 1E6

Website

https://www.aptose.com

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Executives

Bernd Robert Seizinger	Director
William Glenn Rice	Director, Senior Officer
Charles Fletcher Payne	Senior Officer
Erich Platzer	Director
Rafael Bejar	Senior Officer
Warren Whitehead	Director
Gregory Kwok Lee Chow	Senior Officer
Jotin Marango	Senior Officer

Aptose Biosciences Headlines

No Headlines